Literature DB >> 29229705

Proteolytic Processing of Neurexins by Presenilins Sustains Synaptic Vesicle Release.

Emilia Servián-Morilla1,2, Estefanía Robles-Lanuza1,2, Ana C Sánchez-Hidalgo1,2, Rafael J Camacho-Garcia1,2, Juan A Paez-Gomez1,2, Fabiola Mavillard1,2,3, Carlos A Saura3,4, Amalia Martinez-Mir1, Francisco G Scholl5,2.   

Abstract

Proteolytic processing of synaptic adhesion components can accommodate the function of synapses to activity-dependent changes. The adhesion system formed by neurexins (Nrxns) and neuroligins (Nlgns) bidirectionally orchestrate the function of presynaptic and postsynaptic terminals. Previous studies have shown that presenilins (PS), components of the gamma-secretase complex frequently mutated in familial Alzheimer's disease, clear from glutamatergic terminals the accumulation of Nrxn C-terminal fragments (Nrxn-CTF) generated by ectodomain shedding. Here, we characterized the synaptic consequences of the proteolytic processing of Nrxns in cultured hippocampal neurons from mice and rats of both sexes. We show that activation of presynaptic Nrxns with postsynaptic Nlgn1 or inhibition of ectodomain shedding in axonal Nrxn1-β increases presynaptic release at individual terminals, likely reflecting an increase in the number of functional release sites. Importantly, inactivation of PS inhibits presynaptic release downstream of Nrxn activation, leaving synaptic vesicle recruitment unaltered. Glutamate-receptor signaling initiates the activity-dependent generation of Nrxn-CTF, which accumulate at presynaptic terminals lacking PS function. The sole expression of Nrxn-CTF decreases presynaptic release and calcium flux, recapitulating the deficits due to loss of PS function. Our data indicate that inhibition of Nrxn processing by PS is deleterious to glutamatergic function.SIGNIFICANCE STATEMENT To gain insight into the role of presenilins (PS) in excitatory synaptic function, we address the relevance of the proteolytic processing of presynaptic neurexins (Nrxns) in glutamatergic differentiation. Using synaptic fluorescence probes in cultured hippocampal neurons, we report that trans-synaptic activation of Nrxns produces a robust increase in presynaptic calcium levels and neurotransmitter release at individual glutamatergic terminals by a mechanism that depends on normal PS activity. Abnormal accumulation of Nrxn C-terminal fragments resulting from impaired PS activity inhibits presynaptic calcium signal and neurotransmitter release, assigning synaptic defects to Nrxns as a specific PS substrate. These data may provide links into how loss of PS activity inhibits glutamatergic synaptic function in Alzheimer's disease patients.
Copyright © 2018 the authors 0270-6474/18/380901-17$15.00/0.

Entities:  

Keywords:  Alzheimer's disease; neurexins; neuroligins; presenilins; synapse; synaptic adhesion

Mesh:

Substances:

Year:  2017        PMID: 29229705      PMCID: PMC6596238          DOI: 10.1523/JNEUROSCI.1357-17.2017

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  60 in total

1.  Reversal of synaptic vesicle docking at central synapses.

Authors:  V N Murthy; C F Stevens
Journal:  Nat Neurosci       Date:  1999-06       Impact factor: 24.884

2.  Morphological correlates of functionally defined synaptic vesicle populations.

Authors:  T Schikorski; C F Stevens
Journal:  Nat Neurosci       Date:  2001-04       Impact factor: 24.884

3.  Neuroligin expressed in nonneuronal cells triggers presynaptic development in contacting axons.

Authors:  P Scheiffele; J Fan; J Choih; R Fetter; T Serafini
Journal:  Cell       Date:  2000-06-09       Impact factor: 41.582

4.  Inactivity produces increases in neurotransmitter release and synapse size.

Authors:  V N Murthy; T Schikorski; C F Stevens; Y Zhu
Journal:  Neuron       Date:  2001-11-20       Impact factor: 17.173

5.  CASK and protein 4.1 support F-actin nucleation on neurexins.

Authors:  T Biederer; T C Sudhof
Journal:  J Biol Chem       Date:  2001-10-16       Impact factor: 5.157

6.  Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism.

Authors:  Stéphane Jamain; Hélène Quach; Catalina Betancur; Maria Råstam; Catherine Colineaux; I Carina Gillberg; Henrik Soderstrom; Bruno Giros; Marion Leboyer; Christopher Gillberg; Thomas Bourgeron
Journal:  Nat Genet       Date:  2003-05       Impact factor: 38.330

7.  Neurexin mediates the assembly of presynaptic terminals.

Authors:  Camin Dean; Francisco G Scholl; Jenny Choih; Shannon DeMaria; James Berger; Ehud Isacoff; Peter Scheiffele
Journal:  Nat Neurosci       Date:  2003-07       Impact factor: 24.884

8.  Syntenin-syndecan binding requires syndecan-synteny and the co-operation of both PDZ domains of syntenin.

Authors:  J J Grootjans; G Reekmans; H Ceulemans; G David
Journal:  J Biol Chem       Date:  2000-06-30       Impact factor: 5.157

9.  Structure and evolution of neurexin genes: insight into the mechanism of alternative splicing.

Authors:  Katsuhiko Tabuchi; Thomas C Südhof
Journal:  Genomics       Date:  2002-06       Impact factor: 5.736

10.  X-linked mental retardation and autism are associated with a mutation in the NLGN4 gene, a member of the neuroligin family.

Authors:  Frédéric Laumonnier; Frédérique Bonnet-Brilhault; Marie Gomot; Romuald Blanc; Albert David; Marie-Pierre Moizard; Martine Raynaud; Nathalie Ronce; Eric Lemonnier; Patrick Calvas; Béatrice Laudier; Jamel Chelly; Jean-Pierre Fryns; Hans-Hilger Ropers; Ben C J Hamel; Christian Andres; Catherine Barthélémy; Claude Moraine; Sylvain Briault
Journal:  Am J Hum Genet       Date:  2004-02-12       Impact factor: 11.025

View more
  2 in total

Review 1.  Intercellular signaling by ectodomain shedding at the synapse.

Authors:  M Dolores Martín-de-Saavedra; Marc Dos Santos; Peter Penzes
Journal:  Trends Neurosci       Date:  2022-04-13       Impact factor: 16.978

Review 2.  Neurexins: molecular codes for shaping neuronal synapses.

Authors:  Andrea M Gomez; Lisa Traunmüller; Peter Scheiffele
Journal:  Nat Rev Neurosci       Date:  2021-01-08       Impact factor: 34.870

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.